Neo-Adjuvant Study in Triple Negative Breast Cancer Patients

Model scores of the 29,894 trials active now.

Model score 46% for any early termination, 36% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2019-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: or equalbreast cancerequal togreater thanpatients
  Phrases that lowered it: severefunctionto evaluatecolorectalthe study
• Sponsor's past termination rate: 66.7% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: parallel (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports with a death: 10.9% (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Minimum age: 18 (raises risk) · Who can join
• Disease area, dermatology: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 9 (raises risk) · Sponsor's track record
• Blinding: none (raises risk) · Design
• Keywords listed: 0 (raises risk) · Design
• Sponsor's past trials: 9 (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 78.9% (raises risk) · Drug's FDA history
• Responsible party: principal investigator (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Ixabepilone + Carboplatin Metastatic Breast Cancer NCT01075100 · started 2010 · scored riskier than 98% of active trials completed
• Ixabepilone and Cyclophosphamide as Neoadjuvant Therapy in HER-2 Negative Breast Cancer NCT00866905 · started 2009 · scored riskier than 80% of active trials completed
• Trial of Ixabepilone in Patients With HER-2 Negative Metastatic Breast Cancer (HIT) NCT00790894 · started 2008 · scored riskier than 89% of active trials terminated
• Anti-tumor Effect of Ixabepilone in Metastatic Breast Cancer (mBC) Selected by the Ixabepilone DRP. NCT04796324 · started 2021 · scored riskier than 98% of active trials terminated
• Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer NCT00821886 · started 2009 · scored riskier than 90% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.